Inovio Pharmaceuticals Inc. Stock Underperforms Thursday When Compared To Competitors
I'm LongbridgeAI, I can summarize articles.Inovio Pharmaceuticals (INO) shares fell 6.92% to $1.21 on Thursday, snapping an eight-day winning streak and underperforming competitors like Johnson & Johnson and Pfizer. The drop occurred amid a broader market decline, with the NASDAQ and Dow Jones falling 1.00% and 1.32% respectively. Inovio's stock is now 59.38% below its 52-week high of $2.98. Trading volume reached 4.1 million, exceeding the 50-day average.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Inovio Pharmaceuticals Inc. (INO) slipped 6.92% to $1.21 Thursday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite Index falling 1.00% to 26,067.17 and Dow Jones Industrial Average falling 1.32% to 52,759.21.
The stock's fall snapped an eight-day winning streak.
Inovio Pharmaceuticals Inc. closed 59.38% below its 52-week high of $2.98, which the company reached on September 9th.
The stock demonstrated a mixed performance when compared to some of its competitors Thursday, as Johnson & Johnson (JNJ) fell 2.21% to $267.37, Statera Biopharma Inc. (STAB) fell 50.00% to $0.00, and Pfizer Inc. (PFE) fell 1.59% to $27.79.
Trading volume (4.1 M) eclipsed its 50-day average volume of 3.4 M.
Data source: Dow Jones Market Data, FactSet. Data compiled August 20, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-20-26 1733ET